Lakefront Biotherapeutics NV
32.28USD
-0.0500 (-0.15%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on LKFT.
Revenue
| (EUR) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 241.2M | 239.7M | 275.6M | 1.1B | 117.2M | 84.6M |
| Q1 | — | — | — | — | 6.5M | — |
| Q2 | — | — | — | 65.3M | 12.1M | — |
| Q3 | — | — | — | 71.2M | 41.2M | — |
| Q4 | — | — | — | 900.8M | 106.8M | — |
Revenue
| (EUR) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -3.32 | 3.21 | 1.12 | 4.87 | -.710 | -1.06 |
| Q1 | — | — | — | -2.33 | .220 | — |
| Q2 | — | — | — | — | — | — |
| Q3 | — | — | — | — | .230 | — |
| Q4 | — | — |
Fiscal period: Reported, Estimated. Reported figures: Yahoo Finance (limited history). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| — |
| 11.87 |
| -.165 |
| — |
Debt level and coverage